Objective: Resuscitation of hemorrhagic hypotension after traumatic brain injury is challenging. A hemoglobin-based oxygen carrier may offer advantages. The novel therapeutic hemoglobinbased oxygen carrier, polynitroxylated pegylated hemoglobin (PNPH), may represent a neuroprotective hemoglobin-based oxygen carrier for traumatic brain injury resuscitation.
H ypotension from hemorrhage complicating traumatic brain injury (TBI) contributes to secondary injury and poor outcome, including both morbidity and mortality. The deleterious effects of hypotension have been demon-strated in both civilian settings (1) and military settings such as blast injury (2) . Effective resuscitation of combined TBI and hemorrhage is essential to improving outcomes in the increasing numbers of individuals exposed to these combined injuries, particularly in military theaters abroad (3) .
Traditional prehospital strategies for TBI resuscitation involve the administration of isotonic fluids, such as lactated Ringer's (LR) solution, or colloids, such as Hextend (HEX, Hospira, Inc., Lake Forest, IL) (the civilian and military standards of care, respectively) after injury to restore blood pressure and potentially, cerebral perfusion pressure. However, large volumes of resuscitation fluid may exacerbate cerebral edema (4) and fail to increase oxygen delivery. In addition, these solutions fail to specifically target deleterious cascades associated with ischemia reperfusion injury. In the prehospital setting, hemoglobin (Hb)-based oxygen carriers (HBOCs) may offer specific advantages over crystalloids or colloids as a resuscitation fluid in the setting of hemorrhagic hypotension after TBI. HBOC resuscitation may allow for volume expansion by using small amounts of fluid with the potential advantage of restoring oxygen delivery to the injured brain, which exhibits markedly increased metabolic demands and excitotoxicity early after TBI (5) . However, human clinical trials have shown increased morbidity and mortality with the use of HBOCs (6) .
Current-generation HBOCs and cellfree Hb scavenge nitric oxide (NO), resulting in vasoconstriction and decreased oxygen delivery to myocardium and other vascular beds (7) . This could also impair posttraumatic cerebral blood flow (CBF), because NO levels and endothelial NO synthase (NOS1) activity are compromised early after TBI in injured brain regions (8) . Additional putative deleterious side effects of HBOCs have also been suggested. Winslow (9) proposed that increased oxygen delivery caused by free Hb juxtaposed to vascular endothelium causes local hyperoxia with coupled vasoconstriction, which could further impair CBF in the injured brain. Similarly, HBOCs and cell-free Hb can also directly contribute to oxidative stress in both the microcirculation and parenchyma. Specifically, extravasation of cell-free Hb into tissue could result in direct cytotoxiciy, and this could be of considerable importance in TBI, because vascular disruption occurs and classic studies have shown that cell-free Hb is highly neurotoxic in cell culture (10, 11) .
Chemical modification of the Hb structure has been studied to minimize the harmful side effects of HBOCs. Nitroxyl groups have well-known antioxidant effects including potent superoxide dismutase mimetic activity, along with other favorable effects on oxidative stress, such as limiting autoxidation (12) . Polynitroxylation of Hb also creates redox coupling between the covalently labeled nitroxides and the heme iron to provide additional catalase mimetic activity (13) . Pegylation (i.e., adding polyethylene glycol [Peg] moieties to the Hb molecule) pro-vides several potential favorable effects including limiting the Hb from direct interaction with the endothelium-attenuating oxygen mediated vasoconstriction (14) and enhancing nitrite reductase activity-with increased NO production and blunted vasoactivity (15) . Pegylation also adds a "supercolloid" effect to an HBOC, due to the potent water scavenging effect of Peg moieties (Dr. A. Abuchowski, personal communication), and prolongs HBOC half-life. Polynitroxylated pegylated Hb (PNPH) is a novel bovine HBOC developed by SynZyme Technologies (Irvine, CA) that uses Peg-conjugated bovine Hb (Peg-Hb) (Prolong Pharmaceuticals, South Plainfield, NJ) as the starting material and thus has both of these chemical modifications. Specifically, it has ϳ14 nitroxyl radicals (nitroxides) and eight to ten Peg moieties (5-kDa molecular weight each) per Hb tetramer molecule. It is prepared as a 4% Hb solution.
We recently published (16) details of a mouse model in which a mild, controlled cortical impact (CCI) injury to brain was followed by 90 min of volume-controlled hemorrhagic hypotension, resulting in an exacerbation of neuronal death in the vulnerable CA1 hippocampus vs. that seen in either CCI or hemorrhage alone. Blood flow was compromised in the hippocampus beneath the contusion during the hemorrhage. The model is perfectly suited for exploratory evaluation of novel HBOCs in the setting of TBI resuscitation in that it allows for the assessment of acute hemodynamics and long-term outcome including neuropathology. Mortality rates in the model with standard resuscitation solutions range between 25% and 30%. Unlike what is seen for large-animal models, novel therapies can be explored both with extremely small volumes of novel resuscitation fluids and with relatively limited expense.
We tested two hypotheses: 1) PNPH is a unique non-neurotoxic HBOC in neuronal culture and is neuroprotective in in vitro neuronal injury models, and 2) resuscitation with PNPH would require less volume to restore mean arterial blood pressure (MAP) than LR or HEX and confer neuroprotection in a mouse model of TBI plus hemorrhagic hypotension. In the present communication, we present results that show that PNPH is a unique neuroprotective Hb both in vitro and in vivo and that support its further development and evaluation as a neuroprotective HBOC for smallvolume prehospital TBI resuscitation.
METHODS

Primary Cortical Neuronal Cultures
Primary cortical neuron-enriched cultures were prepared from the cerebral cortex of fetal Sprague-Dawley rats (embryonic day 16). Dissociated cell suspensions were plated in 96well plates (5 ϫ 10 4 cells/well) or in silicon dishes coated with poly-D-lysine (3 ϫ 10 6 ). Cells were cultured by using Neurobasal medium, supplemented with B27 (Invitrogen, Carlsbad, CA) and penicillin/streptomycin. The medium was changed every 2-3 days. Cells were maintained in incubators at 37°C in a humidified atmosphere of 5% CO 2 in air. Experiments were performed at 7-10 days in vitro. All studies in primary neuronal culture were replicated in at least three separate experiments by using primary neurons cultured from separate litters and included assay of between nine and 22 wells from three to five different 96-well plates.
Preparation of Hb Solutions
Stroma-free bovine Hb was prepared by crossflow ultrafiltration by using a modified published procedure (17) : Fresh bovine red blood cells were purchased from Innovative Research (Novi, MI). To match with PNPH, each Hb used in the experiments was the carboxy (carbon monoxide [CO]) Hb formulation. Peg-Hb was prepared as follows: The starting material, deoxy Peg-Hb was obtained from Prolong Pharmaceuticals (South Plainfield, NJ) and converted to CO ligand form as a first step, and then the Peg-Hb(CO) was diafiltrated with 8 volumes of saline by using Sartoflow Alpha filtration system (Sartorius Stedim Biotech, Aubagne, France) equipped with 50-kDa molecular weight cut-off membrane cassettes. PNPH was prepared as follows: The polynitroxylation was performed by allowing Peg-Hb(CO) to react with the nitroxide compound 4-(2-bromoacetamido)-2,2,6,6-tetramethylpiperidine-1-oxyl, which was custom synthesized according to SynZyne's standard operating procedure by Chunghwa Chemical Synthesis and Biotech (Taipei, Taiwan). The reaction was carried out at pH 9.0 at 37°C for 4 hrs under 3-PSI CO pressure. A molar ratio of 16 nitroxides per Hb was used to start the reaction. The reaction mixture was then ultrafiltrated with saline. Under optimum conditions, approximately 14 nitroxide moieties can be covalently linked to each Peg-Hb tetramer. All samples, Hb, Peg-Hb, and PNPH, were adjusted to 4% Hb concentration, which is equivalent to 0.62 mM of tetramer or 2.5 mM of heme as determined spectrophotometrically. MetHb was determined to be Ͻ5% spectrophotometrically. Endotoxin was deter-mined to be Ͻ1 unit/mL by Limulus amebocyte lysate method. Labeled nitroxide concentration was measured by electron paramagnetic resonance spectroscopy, and the labeling number of 14 nitroxides per Hb tetramer in PNPH was calculated from the ratio of nitroxide concentration to Hb concentration.
Assessment of Hb-Induced Neurotoxicity
The toxicity of PNPH was compared with its aforementioned parent Hb molecules, specifically, bovine Hb and Peg-Hb in the primary neuronal culture system. For these studies, the Hb dilutions used included 1/50, 1/100, 1/500, and 1/1000. These dilutions yielded the following approximate Hb concentrations (expressed as the concentration of tetramer) for the three preparations, namely 12.50 M, 6.25 M, 1.25 M, and 0.625 M, respectively.
In Vitro Neuronal Injury Models
Glutamate/Glycine (Glu/Gly)-Induced Neuronal Death and In Vitro TBI. Neurons were exposed to 10 M L-Glu/10 M Gly with or without bovine Hb, bovine Peg-Hb, or PNPH in the culture medium for 24 hrs. In vitro TBI was produced by neuronal stretch (18) . A computer-controlled apparatus to stretch neurons at a defined strain magnitude and rate was used. In brief, primary cortical neurons were grown on silicone membranes (0.002-to 0.005-inch thick, Specialty Manufacturing, Saginaw, MI) secured to stainless steel rings that were polished and passivated before use. At 8 days in vitro, cultures were pretreated with varying concentrations of Hb for 30 min. The membranes were then placed over a hollowed platform in a custom-made, sealed, stainless steel chamber. The membranes were then stretched with a preset strain rate (10 s Ϫ1 ) and membrane deformation (50%) by using an air pressure pulse. The pressure waveform was measured and collected on a data acquisition system to verify the degree of insult. Severe stretch was chosen to simulate a strain field similar to that seen in animal models of TBI (18) . Neuronal cultures were then returned to the incubator. Cultures were pretreated with varying concentrations of Hb for 30 min. Between six and eight independent stretch insults were carried out for each condition tested.
Cytotoxicity Detection (Lactate Dehydrogenase [LDH] Release)
Cortical neuronal cell injury was quantified by the measurement of LDH at 24 hrs after the insult. An aliquot of bathing media was combined with NADH and pyruvate solutions. LDH activity is proportional to the rate of pyruvate loss, which was assayed by absorbance change by using a microplate reader (Spectra MAX 340, Molecular Devices, Sunnyvale, CA). Blank LDH levels were subtracted from insult LDH values and results normalized to 100% neuronal death caused by 0.5% Triton X-100 exposure.
Cell Viability (3-[4,5-Dimethylthiazol-2-yl-]-2,5-Diphenyltetrazolium Bromide [MTT] Assay)
Cell viability was evaluated by using the MTT colorimetric assay. MTT (Sigma, St. Louis, MO) is a water-soluble tetrazolium salt that yields a yellowish solution when prepared in medium lacking phenol red. Dissolved MTT is converted to an insoluble purple formazan by cleavage of the tetrazolium ring by the active mitochondrial dehydrogenases of living cells. The MTT solution (5-mg MTT/mL medium) was added to each well 24 hrs after the insult at the final concentration of 250 M and incubated for 3 hrs. The media was removed, and cells were dissolved in dimethyl sulfoxide. Formation of formazan was assessed by measuring the amount of reaction product (absorbance change) by using a microplate reader (Spectra MAX 340).
Groups and Experimental Protocol for In Vivo Studies
The Institutional Animal Care and Use Committee of the University of Pittsburgh School of Medicine approved all experiments. C57BL6 male mice (Jackson Laboratories, Bar Harbor, ME), 12-15 wks of age, and weighing 27.7 Ϯ 0.5 g were housed in controlled environmental conditions and allowed ad libitum food and water until the start of the study. The details of this experimental model of CCI and hemorrhage have been previously published (16) .
Anesthesia was induced with isofluorane 4% in 2:1 nitrous oxide/oxygen via nose cone. Femoral venous and arterial catheters were inserted via inguinal cut-down. Animals were placed in a stereotactic frame; a 5-mm craniotomy was performed, and the bone flap was removed. A brain temperature probe (Physitemp, Clifton, NJ) was inserted into the right parietal cortex via a burr hole. A rectal probe was inserted to monitor body temperature. Brain temperature was controlled with a heat lamp at 37.0 Ϯ 0.5°C throughout the study. After the craniotomy, anesthesia was changed to 1% isofluorane in room air for a 10-min stabilization period.
The time course of CCI and resuscitation is shown in Figure 1 . CCI was performed with a pneumatic impactor (Bimba, Monee, IL) by using a flat 3-mm tip at a velocity of 5 m/s to a depth of 1 mm. This level of injury produces a mild-moderate level of injury with no appreciable loss of CA1 hippocampal neurons and no mortality (16) . After injury, the bone flap is replaced and the craniotomy is immediately resealed with dental cement, and beginning within 5 min, blood was withdrawn from the femoral arterial catheter over 15 min to a total volume of 2.0 mL/100 g, a volume shown to produce a MAP between 35 and 40 mm Hg (hemorrhage phase). Shed blood was stored for later infusion. This phase continued for 90 min total (75 min after the completion of blood withdrawal).
Mice were then resuscitated with 0.1-mL aliquots of LR, HEX (Hospira, Inc.), or PNPH to a goal MAP Ն50 mm Hg for 30 min duration (prehospital phase). Mice continued to receive 1% isofluorane with room air for anesthesia. At the conclusion of this phase, mice were switched to isofluorane 1% in oxygen, and shed blood was rapidly reinfused (definitive care phase). After the shed blood was reinfused, a goal MAP Ն60 mm Hg was obtained by administration of additional resuscitation fluid given in 0.1-mL aliquots, if necessary. Total volume of resuscitation fluid administered in each phase was recorded. After the completion of the definitive care phase, catheters were removed, incisions were closed, anesthesia was discontinued, and mice were placed in supplemental oxygen until they were recovered from anesthesia, at which time they were returned to their cage.
Monitoring
Arterial blood pressure was continuously monitored via femoral venous cannula. Heart rate was monitored continuously and was recorded every 5 min. Arterial blood gasses were obtained at baseline, 30 min after hemorrhage, postresuscitation, and at the end of the definitive care phase. Evaluation of hematocrit, arterial lactate, and blood glucose was also performed at these time points.
Histology
At 7 days after injury, animals were anesthetized with 4% isofluorane and killed by transcardial perfusion fixation with ice-cold saline followed by 10% buffered formalin. Brain tissue was fixed with 10% buffered formalin and embedded in paraffin. Multiple 5-m sections, 200 m apart from bregma Ϫ1.86 to Ϫ2.26, were prepared from each brain. Sections were stained with Fluoro-Jade C (FJC; Chemicon, Temecula, CA) and hematoxylin and eosin (H&E, Thermo Scientific, Pittsburgh, PA), and hippocampal neuronal degeneration was quantified in the dorsal CA1 and CA3 hippocampus underlying the cortical contusion in brain sections stained with FJC by an evaluator blinded to treatment group using ImageJ software (National Institutes of Health, Bethesda, MD). The number of surviving neurons in CA1 and CA3 were also quantified by a blinded observer in the H&Estained sections.
Statistical Analysis
Data are expressed as mean Ϯ SEM or median (range) where appropriate. Analysis of variance was used to compare continuous physiologic variables among groups. Appropriate post hoc analysis was performed including the Student-Neuman-Keuls or Tukey test when a significant analysis of variance result was discovered. Kruskal-Wallis nonparametric analysis was used to determine the significance of nonparametric data.
RESULTS
In Vitro Studies
Hb Toxicity Studies. Exposure of neurons to bovine Hb produced anticipated neurotoxicity based on prior reports (10), and neurotoxicity was seen at all concentrations and dose dependent as assessed by either LDH or MTT assays (Figs. 2 and 3). Based on LDH release, a significant dose response (an ϳ20 -40% cell loss relative to Triton lysis) was observed across concentrations for bovine Hb, with the 1:50 dilution showing significant neuronal death vs. all other concentrations (p Ͻ .05, Fig. 2 ). In the MTT assay, native bovine Hb also showed a dose response for toxicity with the greatest loss of neuronal viability at the highest two concentrations (again p Ͻ .05, Fig. 3 ). Peg-Hb In Vitro Neuronal Injury Models. PNPH also attenuated Glu/Gly-induced neuronal death at all concentrations as determined by LDH and MTT assays (p Ͻ .05, Figs. 4 and 5). The reduction in LDH release by PNPH after Glu/Gly exposure was similar to baseline LDH release in normal neurons in our preparation ( Fig.  4 ). Native bovine Hb at the highest two concentrations further reduced neuronal viability after Glu/Gly, as assessed in the MTT assay ( Fig. 5 ). Native bovine Hb reduced LDH release induced by Glu/Gly but only at 0.625 M (Fig. 4) . Bovine Peg-Hb did not exacerbate neuronal death induced by Glu/Gly and in fact showed intermediate attenuation of Glu/ Gly toxicity assessed by MTT and LDH assays ( Figs. 4 and 5 ). The effect of the three Hb preparations was also assessed in the neuronal stretch model at the 1.25-M concentration with cell death assessed again using both the LDH and MTT assays at 24 hrs ( Fig. 6A and B) . In the stretch model, between 30% and 40% neuronal death was observed (by both assays). Neuronal death from stretch was significantly exacerbated by exposure to native bovine Hb (p Ͻ .05 vs. stretch alone by both LDH and MTT assays). Peg-Hb modestly reduced neuronal death vs. stretch alone in the LDH but not MTT assay, whereas a marked reduction in neuronal death was produced by PNPH (to Յ12% in both LDH and MTT assays, p Ͻ .05 vs. all stretch injury groups including stretch plus Peg-Hb).
In Vivo Experimental TBI Plus Hemorrhagic Hypotension in Mice
To obtain n ϭ 5 survivors in each of the three groups, a total of 20 mice were used. A total of n ϭ 6 animals were resuscitated with PNPH, n ϭ 5 mice were resuscitated with HEX, and n ϭ 9 mice were resuscitated with LR. The trend toward higher mortality in the LR group did not reach significance. Table 1 provides a summary of the resuscitation volume delivered during the prehospital phase of the experiment and the mean and peak MAPs resulting in each phase of the experiment. Resuscitation with PNPH and HEX required less volume than LR (p Ͻ .0001 for PNPH vs. LR and p Յ .05 for HEX vs. LR). When expressed in volume per kilogram dose, PNPH-, HEX-, and LR-treated groups re- Before resuscitation, all three groups had similar initial MAPs (p ϭ .61). Each group had similar mean and peak MAPs during the hemorrhage phase (p ϭ .42 mean MAP, p ϭ .61 peak MAP). The mean MAP for each group during the hemorrhage phase was within a target range of 30 -40 mm Hg and no differences were detected among groups (p ϭ .61). During the prehospital phase, all groups attained mean MAPs Ͼ50 mm Hg. However, the PNPH and HEX groups attained mean MAPs significantly greater than the LR group (p Ͻ .05 for both PNPH vs. LR and HEX vs. LR). Peak MAPs were also higher in the PNPH group vs. LR (p Ͻ .05) but did not differ vs. HEX. Mice resuscitated with PNPH reached goal MAPs by 5 min into the prehospital phase ( Fig. 7) , whereas mice in the HEX and LR groups took between 10 and 15 min despite ongoing fluid administration. After the initial difference among groups at 5 min, mice in the PNPH group trended toward higher MAP vs. both HEX and LR until 25 min into the prehospital phase when the mean MAPs were statistically higher. During the definitive care phase, which began after reinfusion of shed blood, the mean MAPs among groups were not different (p ϭ .19). However, the PNPH group attained higher peak MAPs during the 30 min definitive care phase than HEX (p Ͻ .05 for PNPH vs. HEX). Table 2 provides a summary of hematocrit, lactate, base deficit, and glucose levels throughout the study. In all groups, the hematocrit decreased significantly from baseline values to the hemorrhage phase (p Ͻ .05). Prehospital resuscitation with PNPH, HEX, and LR resulted in postresuscitation hematocrit values that trended lower than, but were not different from, values in the hemorrhage phase. Infusion of shed blood in the definitive care phase appropriately yielded a rise in hematocrit from postresuscitation values in all groups but resulted in hematocrits still lower than baseline val-ues (p Ͻ .05). There were no betweengroup differences in hematocrit noted in any of the phases. There were also no between-group differences in lactate levels, although the lactate did decrease in each group in the definitive care phase vs. earlier phases. There was a significant difference in base deficit in LR-treated mice vs. baseline during hemorrhage, but there were no differences among treatment groups during hemorrhage, and the effect was extremely small and unlikely to be physiologically significant. Glucose levels were also similar among groups at all points during the experiment. Although there was a trend toward lower glucoses in the postresuscitation and definitive care phases, these levels did not reach statistical significance. Table 3 summarizes pH, PaCO 2 , and
Physiology
PaO 2 values during the study. There was no significant change in pH during the study phases or difference among groups. In each group, there was a significant rise in PaCO 2 between the hemorrhage and definitive care phases and between the postresuscitation time point and the definitive care phase. There was a significant decrease in the PaO 2 across groups between the baseline measurements and the hemorrhage phase. There was also a significant increase in PaO 2 in all groups between the postresuscitation time point and the definitive care phase values as expected with the increase in FIO 2 from 0.21 to 1.0.
Neuropathology
Hippocampal sections taken from mice resuscitated with LR and HEX in our combined injury model typically exhibited a focal area of neuronal degeneration in the CA1 region of the hippocampus at 7 days after the insult as reflected by FJC staining (Fig. 8 ). As anticipated, FJC-positive neurons were markedly greater in CA1 than in CA3 in this model (16) . However, the number of FJC-positive neurons found in CA1 was significantly less in mice resuscitated with PNPH (median 3, range [0 -6]) than those resuscitated with HEX (18, [7-48] Hippocampal sections taken from mice resuscitated with LR and HEX typically exhibited thinning of the hippocampus as well as a focal area of neuronal death, as noted in H&E-stained sections by the defect in the contour in the CA1 region of the hippocampus (Fig. 9 ). Sections taken from those animals resuscitated with PNPH showed little evidence of neuronal eosinophilia with pyknotic nuclei indicative of the typical injury to CA1 seen in this model. The linear density of neurons in CA1 (Fig. 10) H&E staining in HEX and LR groups is comparable to that of our prior report in this model (16) .
DISCUSSION
This study is the first to examine PNPH as a therapeutic HBOC. Based on our work in in vitro models, we report that unlike native Hb, PNPH exhibits a unique lack of neurotoxicity as assessed with multiple assays of cell viability in rat primary neuronal culture, and surprisingly, PNPH is neuroprotective in in vitro models of both excitotoxicity and TBI (neuronal stretch). In vivo, using an established murine model of TBI plus hemorrhagic hypotension (16, 19) , the use of a PNPH solution as a resuscitation fluid, like the colloid HEX, conferred an advantage over LR as being a small-volume resuscitation solution, but PNPH also produced a potentially more favorable hemodynamic response than either LR or HEX. Importantly, mirroring the in vitro studies, PNPH produced unique neuroprotection in selectively vulnerable CA1 beneath the contusion in our model. Each of these effects deserves further discussion.
Specific Properties of PNPH. The PNPH used in these studies is a covalently modified (polynitroxylated) version of a well-characterized bovine Peg-Hb (Prolong Pharmaceuticals, South Plainfield, NJ) (20) . It has a P50 of 11 and it contains ϳ14 nitroxide moieties and eight to ten Peg moieties that are covalently linked. It is prepared as a 4% solution. Based on a formulation containing a 4% solution, it is being developed as a small-volume, antioxidant, neuroprotective resuscitation fluid rather than a current-generation blood replacement therapy. With regard to in vivo resuscitation, LR, HEX, and PNPH have osmolarities of 273, 307, and ϳ308, respectively.
Lack of Neurotoxicity of PNPH In Vitro. As anticipated, native bovine Hb showed dose-dependent neurotoxicity in our in vitro system (10, 11) . Neurotoxic- ity was blunted by pegylation, although it was still evident at all concentrations for Peg-Hb. In contrast, PNPH was devoid of neurotoxicity across concentrations and assays in our culture system. Regan and Panter (10) reported dose-dependent neurotoxicity (LDH release) in a mixed cortical culture containing both neurons and glia exposed to purified human Hb concentrations between 0.025 and 25 M (based on the tetramer) for 24 -48 hrs. Supporting a key potential role for oxidative injury, neurotoxicity was markedly attenuated by the antioxidant Trolox, the 21-aminosteroid U745000A, or the iron chelators deferoxamine or phenanthroline (10, 21) . Oxidative damage to the cell membrane or membrane bound enzymes was suggested to mediate these findings, and iron release from Hb may be important (22) . We noted similar results for bovine Hb at concentrations of 0.625-12.50 M (based on the tetramer) at 24-hr exposure. Thus, the neurotoxicity of Hb may be abrogated by PNPH via its covalently linked nitroxides, which confer superoxide dismutase mimetic effects and other antioxidant actions. However, based on our data, pegylation also partially blunts the neurotoxicity. Thus, other effects such as accessibility or stability of the Hb moiety could also contribute to this favorable effect of PNPH. The unique lack of neurotoxicity of PNPH could be quite important in TBI resuscitation if an HBOC is contemplated as a therapy since blood-brain barrier damage and hemorrhage are well-known complications of TBI and thus resuscitation with a conventional cell-free Hb could cause direct neurotoxicity locally in the injured brain.
In Vitro Neuroprotection by PNPH. Based on prior work (11), we did not anticipate dramatic augmentation of glutamate-mediated neuronal death by the Hb preparations that we examined. Minimal increases in LDH release by human Hb were seen in the mixed murine neuron and glial cultures exposed to the excitotoxic agent N-methyl-D-aspartate at a 9 M concentration. Our data with Glu/ Gly exposure at 10 M also suggest only modest augmentation of excitotoxic neuronal death by bovine Hb at the highest concentrations tested. We were, however, surprised that PNPH was neuroprotective against Glu/Gly toxicity at all concentrations and that even Peg-Hb showed some protection. Although the mechanisms underlying the neuroprotective effect of PNPH remain to be defined, oxidative damage is a key facet of excitotoxicity. Relevant to protection by PNPH, excitotoxic injury was recently shown to involve a critical role for neuronal membrane bound nicotinamide-adenine dinucleotide phosphatase oxidase-mediated oxidative damage (23) . Because PNPH would be expected to be confined to the extracellular space, this is an attractive target. Redox effects directly on the N-methyl-D-aspartate receptor could also reduce excitotoxicity (24) . Finally, because Peg-Hb conferred intermediate neuroprotection, other effects could be operating. PNPH also showed protection in the in vitro TBI model system as shown again by using both LDH and MTT assays. Given our results in the Glu/Gly model, this finding might be anticipated because excitotoxicity plays a major role in mediating neuronal death in the stretch model (18) .
Small-Volume Resuscitation Effects of PNPH on Hemodynamics. PNPH required significantly less volume than LR to achieve target MAP in mice subjected to TBI plus hemorrhage. PNPH required approximately one-fifth of the volume as LR, whereas HEX required approximately onethird the volume as LR. Small-volume resuscitation with HEX or HBOCs may be quite effective in the setting of acute hemorrhage after TBI (25) (26) (27) . However, the ability to consistently maintain the prehospital target MAP of 50 mm Hg was better with PNPH than with either LR or HEXeven when using this conservative MAP goal. The ability of an HBOC to more rapidly achieve a target MAP of 50 mm Hg, however, could be viewed as either beneficial or detrimental. Small-volume resuscitation after TBI confers protection against the development of brain edema and intracranial hypertension (4) . Better recovery of MAP could be beneficial by more promptly restoring CBF if cerebral perfusion pressure is below the autoregulatory limit, or if blood pressure autoregulation of CBF is impaired, which is common after TBI (28) . However, in the setting of polytrauma with uncontrolled bleeding, the target MAP may need to be conservative to limit bleeding (29) . We chose a MAP of 50 mm Hg in the prehospital phase to simulate a clinical scenario where ongoing bleeding outside of the brain might limit the ability to attain a "normal" MAP while providing the lowest acceptable MAP for cerebral perfusion. Also, scavenging of NO by an HBOC could lead to inappropriate vasoconstriction that could compromise both systemic recovery from hemorrhage and CBF (7) . Our findings, however, argue against this possibility because PNPH did not worsen postresuscitation lactate or pH and also produced neuroprotection, unlike either LR or HEX. Potentially favorable properties related to pegylation could play a role in mediating some of the observed hemodynamic effects of PNPH. Pegylation of proteins confers "supercolloid" effects. Theoretically, each strand of Peg binds 132 molecules of water (Abuchowski, personal communication); thus, each PNPH molecule can potentially bind Ͼ1000 water molecules. This would be anticipated to provide significant oncotic advantages to PNPH and Peg-Hb vs. either HEX, which is generally felt to have oncotic effects similar to 5% albumin (30, 31) , or the crystalloid LR. This could attenuate brain edema while expanding vascular volume. Thus, our data suggest that for a reasonable, albeit conservative, target prehospital MAP, resuscitation with PNPH confers important advantages over LR or HEX.
Neuroprotective Effects of PNPH In Vivo. We observed neuroprotection by PNPH resuscitation at 7 days after injury that was not seen with either LR or HEX. We previously examined resuscitation with LR, HEX, or 3% saline in this model, and none of these solutions conferred neuroprotection in CA1 (19) . Our current report confirms this finding for both LR and HEX. Several other studies have shown beneficial effects of HBOC-201 based resuscitation on cerebral perfusion pressure, intracranial pressure, brain edema, brain tissue oxygen levels, and neuropathology in pig models of TBI plus hemorrhage (25) (26) (27) . Unique in our studies in mice is the assessment of neuropathology at 7 days after injury. Studies in large-animal models have focused on very short-term outcomes (generally 6 -8 hrs), and it has long been known that ischemia-induced neuronal death in CA1 can be delayed, often beyond 2 days (32) . We observed neuroprotection by PNPH in the hippocampus, which is beneath the contusion and may represent a penumbra in the injured hemisphere. It is a region where the blood-brain barrier is disrupted (33) and where there would be concerns over HBOC extravasation into injured brain. In contrast, prior reports with other HBOCs in large-animal models have seen protection limited to sites remote from the impact (27) .
The neuroprotection could be partially explained by the improved MAP seen in mice resuscitated with PNPH vs. HEX or LR. However, because both PNPH and HEX represented small-volume resuscitation solutions in our model but only PNPH conferred neuroprotection, limitation of volume administration alone cannot explain the observed benefit. Nevertheless, the ability of PNPH to promptly and consistently achieve the target prehospital MAP of 50 mm Hg may prevent a cascade of secondary injury.
PNPH may facilitate oxygen delivery to the hippocampus beneath the contusion. However, the amount of oxygen carrying capacity from ϳ6 mL/kg of a 4% PNPH solution during resuscitation is modest when compared with the amount of Hb lost via hemorrhage in our model (ϳ30% blood volume). The P50 of 11 (although lower than the normal P50 of ϳ28 for Hb in erythrocytes) is relatively high for an HBOC (6) . The ability of HBOCs to approach the vascular endothelium can yield greater than anticipated oxygen delivery. A 500-mL infusion of the non-nitroxylated parent Peg-Hb (Prolong Pharmaceuticals, South Plainfield, NJ) formulation used in our studies substantially improved oxygen delivery in a pig model of hemorrhagic shock (20) . It is thus possible that some of the neuroprotection afforded by PNPH is related to enhanced cerebral oxygen delivery. We are currently examining hippocampal brain tissue PO 2 during PNPH resuscitation.
PNPH also contains ϳ14 nitroxide moieties that provide antioxidant and superoxide dismutase mimetic effects. Free nitroxides exhibit neuroprotective effects in experimental TBI. Zhang et al (12) reported a reduction in brain edema and blood-brain barrier permeability in a rat model of TBI by treatment with Tempol. Deng-Bryant et al (34) reported that Tempol attenuated neurodegeneration after CCI in mice as assessed with silver staining. Leker et al (35) showed benefit from Tempol in experimental stroke. Further supporting a role of the nitroxides of PNPH, a polynitroxylated albumin solution reduced vascular injury in models of ischemia reperfusion (36, 37) , conferred neuroprotection in stroke in rats (38) , and improved survival in experimental hemorrhage (39) . PNPH, by reducing superoxide, may limit NO loss to peroxynitrite formation. This would confer a dual benefit-limiting NO consumption and attenuating peroxynitrite production. One might not expect that antioxidant moieties decorating a large molecule like Hb could contribute to neuroprotection in parenchyma. However, our in vitro data argue strongly against that premise. Further studies are needed to define the effects of PNPH on oxidative stress in our models.
Finally, the PNPH used in these studies was a carboxy (CO) Hb PNPH formulation. CO protects the Hb iron during the synthetic addition of the nitroxide moieties. CO inhalation confers cytoprotection in several model systems, possibly via effects on P38 kinase or oxidative stress (40) . Koehler et al (41) , in preliminary studies, reported that CO Hb levels increase to ϳ5% after a 20-mL/kg topload with PNPH and then decrease back to baseline over ϳ2 hrs in rats. This suggests that PNPH may deliver CO to injured brain early in resuscitation. This would also argue that PNPH is unlikely to confer direct neuroprotection via enhanced oxygen delivery, at least during the prehospital phase. It has been shown, however, that unlike inhalation of CO, transfusion of blood with high levels of CO to dogs does not produce toxicity (42) . The possible role of CO in mediating the neuroprotective effects of PNPH in TBI merits additional study.
Unique Aspects of Resuscitation in the Setting of TBI Plus Hemorrhage. Free Hb binding to NO at the endothelium produces vasoconstriction and systemic hypertension (7) . Deleterious effects of current-generation HBOCs in humans likely result from coronary artery constriction via this mechanism. Studies have investigated the delivery of inhaled NO or other vasodilators during HBOC use to prevent vasoconstriction (43) . However, after TBI, some vasopressor action may be tolerated or even advantageous. The use of pressors after TBI may minimize resuscitation fluid volume (44) . Use of large fluid volumes during resuscitation may exacerbate brain edema. Although the use of pressors in the setting of hemorrhagic shock is controversial, a resuscitation fluid with some intrinsic vasopressor action may limit fluid volumes and brain edema.
Limitations of the Study
We recognize that cell culture systems do not include a number of endogenous antioxidant defenses that are present in brain tissue (10) . In our in vivo studies, although we showed benefit of PNPH on both hemodynamics and neuroprotection, there are several limitations. We focused on acute hemodynamics and 7-day neuropathology. We are currently assessing other outcomes including brain tissue oxygen, intracranial pressure, bloodbrain barrier, CBF, and behavior. It is also not clear what the optimal target MAP is in TBI plus hemorrhage (45) . The chosen target MAP of 50 mm Hg is reasonable, but other targets could yield different results. We did not reinfuse shed blood until completion of the prehospital phase to maximize clinical relevance and we recognize that the effect of immediate resuscitation with blood was not explored. Effects of volatile anesthetics such as isofluorane could influence the target MAP after TBI and neuroprotection (46) ; however, it is the most commonly used anesthetic in experimental TBI (47) . We did not monitor total Hb levels in this exploratory study with PNPH. Currently, using a similar protocol we noted that 20 mL/kg of 4% PNPH does not appreciably increase total Hb levels, suggesting that it is unlikely that use of only ϳ6 -7 mL/kg of PNPH in this study would significantly increase arterial Hb level. This may also be related to plasma volume expansion produced by the Peg moieties. We noted greater neuroprotection assessed by FJC staining than with H&E, which may be related to greater sensitivity of FJC in assessing damage. Blood glucose levels were generally in the low normal range and a hyperglycemic response was not observed. However, glucose levels did not differ among groups. We used room air during the prehospital phase. The use of supplemental oxygen could alter the efficacy of an HBOC. Given that this work was supported by the U.S. Army, we chose to simulate the combat casualty care scenario where oxygen is not used in the field due to tactical factors.
CONCLUSIONS
PNPH is a unique non-neurotoxic therapeutic HBOC with novel neuroprotective effects in both in vitro and in vivo TBI models. Limited fluid resuscitation of TBI plus hemorrhagic hypotension in mice by using PNPH offers advantages over LR or HEX, including better normalization of MAP and neuroprotection. The mechanisms underlying the neuroprotection produced by PNPH deserve further exploration.
